Tango Therapeutics, Inc.

TNGX

US87583X1090

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
7.76 ^USD	-0.13%		+4.02%	-21.62%

Apr. 04	British billionaire Joe Lewis fined $5 million by US judge for insider trading	RE
Apr. 04	Multibillionaire Joe Lewis to face US sentencing for insider trading	RE

Bctg Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021

May 14, 2021 at 03:59 pm EDT

BCTG Acquisition Corp. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 265,895. Net loss was USD 239,754.

Latest news about Tango Therapeutics, Inc.

British billionaire Joe Lewis fined $5 million by US judge for insider trading	Apr. 04	RE
Multibillionaire Joe Lewis to face US sentencing for insider trading	Apr. 04	RE
Cantor Fitzgerald Initiates Coverage on Tango Therapeutics With Overweight Rating	Apr. 04	MT
H.C. Wainwright Adjusts Price Target on Tango Therapeutics to $17 From $16, Keeps Buy Rating	Mar. 20	MT
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q4 Revenue $5.4M	Mar. 18	MT
Tango Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 18	CI
Tango Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 18	CI
Tango Therapeutics, Inc.(NasdaqGM:TNGX) added to S&P Biotechnology Select Industry Index	Mar. 17	CI
Transcript : Tango Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:30 AM	Mar. 13
Piper Sandler Initiates Tango Therapeutics With Overweight Rating	Feb. 12	MT
British billionaire Joe Lewis intends to plead guilty to US charges, lawyer says	Jan. 24	RE
Tango Therapeutics Doses First Patient in Phase 1/2 Trial of Cancer Treatment TNG348	Jan. 03	MT
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of Tng348 in Patients with Brca1/2-Mutant and Other Hrd+ Cancers	Jan. 03	CI
B. Riley Starts Tango Therapeutics With Buy Rating, $16 Price Target	Dec. 08	MT
Tango Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Earnings Flash (TNGX) TANGO THERAPEUTICS Reports Q3 Revenue $10.7M	Nov. 08	MT
Tango Therapeutics, Inc. Announces Board Changes	Nov. 08	CI
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday	23-10-18	MT
Tango Therapeutics Discloses Boxer Capital Acquired 1.3 Million Shares; Tango Stock Jumps in Premarket Activity	23-10-18	MT
Tango Therapeutics Receives FDA Clearance to Start the TNG348 Phase 1/2 Clinical Study	23-09-11	CI
Tango Therapeutics Says FDA Cleared Application for Investigational Cancer Treatment TNG348	23-09-06	MT
Tango Therapeutics Announces FDA Clearance of Investigational New Drug Application for Tng348, A Novel Usp1 Inhibitor for the Treatment of Brca1/2-Mutant and Other HRD+ Cancers	23-09-06	CI
Tango Therapeutics Files Prospectus for Sale of 15.5 Million Shares	23-09-01	MT
Tango Therapeutics, Inc. Announces Board Changes	23-08-29	CI
Tango Therapeutics, Inc. announced that it has received $80.016604 million in funding	23-08-23	CI

Chart Tango Therapeutics, Inc.

Duration

Period

More charts

Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Tango Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.76 USD

Average target price

17.57 USD

Spread / Average Target

+126.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
TANGO THERAPEUTICS, INC.	-21.62%	828M
IQVIA HOLDINGS INC.	+4.09%	43.84B
LONZA GROUP AG	+46.28%	41.25B
MODERNA, INC.	+9.45%	41.68B
CELLTRION, INC.	-10.92%	27.04B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.18B
MEDPACE HOLDINGS, INC.	+29.70%	12.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research

Tango Therapeutics, Inc.

Equities

TNGX

US87583X1090

Biotechnology & Medical Research

Bctg Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021

Latest news about Tango Therapeutics, Inc.

Chart Tango Therapeutics, Inc.

Company Profile

Income Statement Evolution

Ratings for Tango Therapeutics, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research